USANA Health Sciences (NYSE:USNA) Stock Rating Raised to “Hold” at Zacks Research

Zacks Research upgraded shares of USANA Health Sciences (NYSE:USNA) from a strong sell rating to a hold rating in a research report report published on Monday,Zacks reports.

A number of other research analysts have also weighed in on the company. Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, USANA Health Sciences has an average rating of “Reduce”.

USANA Health Sciences Stock Up 0.4%

Shares of NYSE:USNA opened at $14.91 on Monday. The stock’s 50 day moving average is $15.15 and its 200-day moving average is $17.85. USANA Health Sciences has a twelve month low of $12.57 and a twelve month high of $26.76. The firm has a market capitalization of $275.61 million, a price-to-earnings ratio of -12.33, a PEG ratio of 1.63 and a beta of 0.68.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The business had revenue of $223.27 million during the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Equities research analysts anticipate that USANA Health Sciences will post 0.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On USANA Health Sciences

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in USANA Health Sciences during the 2nd quarter worth about $33,182,000. Pzena Investment Management LLC purchased a new position in shares of USANA Health Sciences during the second quarter worth approximately $25,739,000. Empowered Funds LLC purchased a new stake in USANA Health Sciences during the second quarter valued at about $1,500,000. Nantahala Capital Management LLC bought a new position in USANA Health Sciences during the 2nd quarter worth approximately $17,295,080. Finally, Bank of New York Mellon Corp purchased a new position in shares of USANA Health Sciences in the second quarter worth $1,105,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, personal-care products and foods designed to support general health and wellness. Its product portfolio includes vitamins and mineral supplements, herbal and specialty nutritional products, meal-replacement and snack items, and skincare products marketed under the USANA and Sensé brands.

Founded in 1992 by immunologist Myron Wentz, USANA distributes its products primarily through a direct-selling model involving independent associates.